]>
IRCT20160310026998N12 IRCT 2020-08-19 Tabriz University of Medical Sciences Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathy Assessment of the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathy: double-blind randomized clinical trial 2020-08-22 anticipated 180 Complete https://irct.ir/trial/49520 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: 180 patients with cancer who are candidates for chemotherapy treatment and referred to the clinic or hospital ward of Shahid Ghazi Hospital will be screened and will select by including & excluding criteria. Patients will then be divided into two groups through simple randomization procedure based on a table of random numbers, Blinding description: Patients with a variety of cancers, who will be candidates for the study based on the including & excluding criteria , will enter the study after completing informed consent, but will not be aware of the main drug or placebo. Also, physicians assisting the researcher who prescribe the drug, will not inform the type of main drug or placebo. 3 chemotherapy-induced peripheral neuropathy in patients with cancer. Intervention 1: Intervention group: Patients undergoing chemotherapy with symptoms of peripheral neuropathy first receive memantine at a dose of 5 mg for three days, and every three days 5 mg is added to the previous dose, and finally at a dose of 20 mg, treatment will continue for eight weeks. Intervention 2: Control group: Patients undergoing chemotherapy with symptoms of peripheral neuropathy as a placebo group will receive placebo for 8 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I haven't decided yet - the release schedule is still unknown
public saba Ghaffary
Shahid Ghazi hospital, Tabriz University of Medical Sciences, Daneshgah street
tabriz Iran (Islamic Republic of) 14766 - 51664 +41 33365010 ghaffarys@tbzmed.ac.ir Tabriz University of Medical Sciences scientific Saba Ghaffry
Shahid Ghazi hospital,Tabriz University of Medical Sciences, Daneshgah street
tabriz Iran (Islamic Republic of) 14766 - 51664 +41 33365010 ghaffarys@tbzmed.ac.ir Tabriz University of Medical Sciences Iran (Islamic Republic of) People with any malignancy who have had grade 2 or higher neuropathy following chemotherapy no limit no limit Both Patients with hypertension Acute heart failure type 1 & 2 diabetes mellitus peripheral vascular disease 285/5000Patients taking drugs (amantadine, ketamine, dextromethorphan, L-dopa; dopaminergic, anticholinergic agonists, barbiturates, neuroleptics, IMAO, antispasmodics, dantrolene or baclofen, phenytoinquinotine, cimetidine, ranitidine And warfarin) alcohl use People of reproductive ages, pregnancy and lactation People taking other neuropathic medications such as gabapentin, pregabalin and dologestin Patients with brain or leptomeningeal metastasis G90.0 Idiopathic peripheral autonomic neuropathy Treatment - Drugs Treatment - Drugs Intervention group: Patients undergoing chemotherapy with symptoms of peripheral neuropathy first receive memantine at a dose of 5 mg for three days, and every three days 5 mg is added to the previous dose, and finally at a dose of 20 mg, treatment will continue for eight weeks. Control group: Patients undergoing chemotherapy with symptoms of peripheral neuropathy as a placebo group will receive placebo for 8 weeks. Severity of neuropathic symptoms. Timepoint: At PRE intervention (baseline phase) & 8 weeks after intervention. Method of measurement: McGill pain questionnaire, Neuropathic Pain, Neuropathic Pain Symptom Inventory. Tabriz University of Medical Sciences Approved 2020-06-06 Ethics Committee at Tabriz University of Medical Sciences Shahid Ghazi hospital, Tabriz University of Medical Sciences, Daneshgah street tabriz East Azarbaijan Iran (Islamic Republic of)